ArticleAnnals of translational medicine2020
Development of a deep learning model for classifying thymoma as Masaoka-Koga stage I or II via preoperative CT images.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Machine Learning-Based Prediction of Masaoka-Koga Stage and WHO Histological Risk Group in Thymic Epithelial Tumors Using Biomarker Combinations.Diagnostics (Basel, Switzerland) · 2026Article
- Deep Learning-Assisted Detection and Classification of Thymoma Tumors in CT Scans.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Artificial intelligence for diagnosis and prognosis of thymic epithelial tumors: a systematic review.Mediastinum (Hong Kong, China) · 2025Review
- Machine learning-based radiomics analysis in enhancing CT for predicting pathological subtypes and WHO staging of thymic epithelial tumors: a multicenter study.American journal of cancer research · 2025Article
- Risk stratification of thymic epithelial tumors based on peritumor CT radiomics and semantic features.Insights into imaging · 2024Article
- Detection of Thymoma Disease Using mRMR Feature Selection and Transformer Models.Diagnostics (Basel, Switzerland) · 2024Article
- Deep learning for risk stratification of thymoma pathological subtypes based on preoperative CT images.BMC cancer · 2024Article
- Re-evaluation and operative indications after induction therapy for thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2024Review
- Thymoma with systemic lupus erythematosus and immune-related anemia: A case of thymoma with SLE and IRA.Medicine · 2022Article
- Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.Current oncology (Toronto, Ont.) · 2022Article
- A CT-Based Radiomic Signature for the Differentiation of Pulmonary Hamartomas from Carcinoid Tumors.Diagnostics (Basel, Switzerland) · 2022Article
- The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.Journal of thoracic disease · 2021Review
- CT imaging-based machine learning model: a potential modality for predicting low-risk and high-risk groups of thymoma: "Impact of surgical modality choice".World journal of surgical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate thymoma staging via computed tomography (CT) images is difficult even for experienced thoracic doctors. Here we developed a preoperative staging tool differentiating Masaoka-Koga (MK) stage I patients from stage II patients using CT images.
methodsCT images of 174 thymoma patients were retrospectively selected. Two chest radiologists independently assessed the images. Variables with statistical differences in univariate analysis were adjusted for age, sex, and smoking history in multivariate logical regression to determine independent predictors of the thymoma stage. We established a deep learning (DL) 3D-DenseNet model to distinguish the MK stage I and stage II thymomas. Furthermore, we compared two different methods to label the regions of interest (ROI) in CT images.
resultsIn routine CT images, there were statistical differences (P<0.05) in contour, necrosis, cystic components, and the degree of enhancement between stage I and II disease. Multivariate logical regression showed that only the degree of enhancement was an independent predictor of the thymoma stage. The area under the receiver operating characteristic curve (AUC) of routine CT images for classifying thymoma as MK stage I or II was low (AUC =0.639). The AUC of the 3D-DenseNet model showed better performance with a higher AUC (0.773). ROIs outlined by segmentation labels performed better (AUC =0.773) than those outlined by bounding box labels (AUC =0.722).
conclusionsOur DL 3D-DenseNet may aid thymoma stage classification, which may ultimately guide surgical treatment and improve outcomes. Compared with conventional methods, this approach provides improved staging accuracy. Moreover, ROIs labeled by segmentation is more recommendable when the sample size is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.